Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies

Launched by NATIONAL CANCER INSTITUTE (NCI) · Mar 20, 2007

Keywords

ClinConnect Summary

This clinical trial is a follow-up study for patients who have previously received a specific type of vaccine treatment for various cancers, including prostate, liver, breast, colon, and lung cancer. The main goal of the study is to monitor the long-term health of these patients to ensure they are doing well and to check for any potential side effects from the treatment they received. Participants in this study will have an annual health check for 15 years, which includes a medical history review, physical exams, and phone check-ins. This is important because while the risks of long-term issues from the vaccine are low, regular monitoring helps keep everyone informed about their health.

To be eligible for this study, individuals must be at least 18 years old and have previously received the poxviral vector vaccines (like vaccinia or fowlpox) as part of a trial at the National Cancer Institute or related studies. Participants can still take part in other treatments or care programs while being involved in this follow-up study. This study aims to gather important health information, including checking for any new health problems or changes, so that patients can continue to receive the best care possible.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Subjects who received poxviral vectors (vaccinia and/or fowlpox) or other vaccines utilizing gene transfer or any other immunotherapeutic agent through GMB, UOB and LTIB affiliated trials at the National Cancer Institute, as well as subjects at extramural sites receiving these agents as part of a multi-site trial. Available stored specimens obtained from NCI participants in GMB, UOB, and LTIB affiliated protocols may be transferred to this protocol for storage and eventual future research use.
• • Subjects must be \>= 18 years of age.
• EXCLUSION CRITERIA:
• • Participants unwilling to participate.
• • (Please note, participants may participate in this protocol and, at the same time, participate in an active treatment or continuing care study.)